Neuralink

Neuralink is at the forefront of brain-computer interface (BCI) technology, developing innovative solutions that enable direct communication between the human brain and external devices. Founded in 2016, the company has raised approximately $1.3 billion, with its latest Series E funding round securing $650 million in June 2025. Neuralink's groundbreaking system features ultra-thin flexible electrode threads, a compact implantable chip, and a specialized surgical robot, allowing paralyzed individuals to control digital devices using only their thoughts.

What sets Neuralink apart is its high channel count technology, which can record from over 1,000 neurons simultaneously, providing precise control for users. The company’s first human patient, implanted in early 2024, successfully demonstrated the ability to control a computer mouse and play chess through thought alone. Neuralink's business model combines hardware, software, and surgical procedures, initially targeting hospitals to provide its premium BCI system to patients with severe neurological conditions.

Looking ahead, Neuralink aims to expand its applications beyond paralysis, with plans to explore vision restoration and treatments for neurological disorders like depression and anxiety. The potential market for these innovations could reach hundreds of billions annually. With a vision of creating "symbiosis with AI," Neuralink aspires to revolutionize not just medical technology but also the way humans interact with machines, potentially making its implants as ubiquitous as smartphones.